Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan Abstract #1788

Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Aim(s): We planned a retrospective and prospective observational study on the prognosis of patients with unresectable advanced GEP-NENs (PROP-UP 1 and 2). PROP-UP 1 is a retrospective multicenter study to estimate a cut-off value of Ki-67 index between G1 and G2. PROP-UP 2 is a prospective study to verify the results of PROP-UP 1. In this paper we analyzed the characteristics of patients registered to PROP-Up 1.
Materials and methods: PROP-UP 1 included individuals diagnosed with advanced (unresectable or recurrent after curative resection) GEP-NENs from January 2012 up to IRB approval. The primary endpoint is overall survival from diagnosis to last follow-up or death. The main secondary endpoint is to assess a cut-off value of Ki-67 index between G1 and G2.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kazuhiro Toriyama
Keywords: prop-up, japan, gep-nen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan
Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD,PhD Yasunari Sakamoto
Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, ...
Keywords: Streptozocin, pNETs
#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System
Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors: Masui T, Imamura M, Ito T, Unno M, ...
#814 Chromogranin A is a Useful Marker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction: Although Chromogranin A (CgA) is known as a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, the usefulness of CgA in Japanese patients with pNETs is unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Masayuki Hijioka
Authors: Hijioka M, Ito T, Igarashi H, Ueda K, ...
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1668 Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3
Introduction: The classification of lung neuroendocrine neoplasms (Lung-NENs) according to the WHO classification 2010 for GEP-NENs, including a provisional category for Lung-NET G3 with Ki67 >20%, may have prognostic implications.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Authors: Kasajima A, Oka N, Ishida H, Sakurada A, ...
Keywords: Lung NEN